MedTrace Logo

Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma

NCT07365839 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-03-25

No results posted yet for this study

Summary

Randomized, 2-arm, non-comparative, pilot study assessing the efficacy of cemiplimab with or without fianlimab after treatment with yttrium-90 (Y90).

Conditions

Interventions

DRUG

Arm 1 cemiplimab

Cemiplimab 350mg IV every 3 weeks up to 1 year.

DRUG

Arm 2 cemiplimab and fianlimab

Cemiplimab 350mg IV and fianlimab 1600mg every 3 weeks up to 1 year

Sponsors & Collaborators

Principal Investigators

  • Emily Kinsey, MD · Virginia Commonwealth University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2035-02-28
Completion
2035-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07365839 on ClinicalTrials.gov